GlassScriptPhysician profile
Devell R Young
NPI 1205822657
$17,002.06
in general payments reported to CMS, 2019-2025
55 companies · $2,039 in 2025
The $2,039 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,870 · 2020: $2,136 · 2021: $2,293 · 2022: $2,420 · 2023: $2,721 · 2024: $2,523 · 2025: $2,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,211 · Education: $72.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,211.27 |
| Education | $72.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,232.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,435.38 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,379.94 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $948.82 | 2019-2025 | |
| Lilly USA, LLC | $890.13 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $755.12 | 2019-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $661.66 | 2022-2025 | |
| Dexcom, INC. | $647.55 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $639.38 | 2019-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $587.65 | 2019-2024 | Verquvo, Capvaxive, Steglatro |
| Astellas Pharma US INC | $523.47 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $516.28 | 2019-2025 | Linzess, Viberzi |
| Janssen Pharmaceuticals, INC | $509.12 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $432.03 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $413.03 | 2019-2025 | Eliquis, Camzyos |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devell Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.